# Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

> **NCT00759837** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer
- Leukemia, Myeloid, Chronic

## Interventions

- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT00759837
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2009-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759837, "Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00759837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*